You are here

  • Home
  • Archive
  • Volume 89, Issue 11
  • Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease

Article Text

Article menu
Download PDFPDF
Clinical science
Scientific reports
Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease
  1. M Kitamura1,4,
  2. N Kitaichi1,
  3. M Takeuchi2,
  4. H Kitamei1,4,
  5. K Namba1,
  6. S-i Yamagishi3,
  7. K Iwabuchi4,
  8. K Onoé4,
  9. S Ohno1
  1. 1Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  2. 2Department of Pathophysiological Science, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan
  3. 3Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan
  4. 4Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
  1. Correspondence to: Mizuki Kitamura MD, Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan; mizukita825ybb.ne.jp

Abstract

Background/aims: Advanced glycation end products (AGEs) are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceraldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. The aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease.

Methods: Sera were obtained from 31 patients with active VKH. 20 of these 31 patients were treated with systemic corticosteroids. As controls, 33 healthy volunteers were also examined. The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody.

Results: The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23) U/ml, which was significantly lower than that of the healthy control subjects (8.32 (2.94), p<0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U/ml after the patients were treated with systemic corticosteroids (p<0.001).

Conclusions: These results suggest that AGE-2 may be involved in the onset of VKH disease.

  • AGEs, advanced glycation end products
  • EAAU, experimental autoimmune anterior uveitis
  • ELISA, enzyme linked immunosorbent assay
  • RAGE, receptor for AGE
  • VKH, Vogt-Koyanagi-Harada
  • Vogt-Koyanagi-Harada disease
  • advanced glycation end products
  • melanocyte
  • AGEs, advanced glycation end products
  • EAAU, experimental autoimmune anterior uveitis
  • ELISA, enzyme linked immunosorbent assay
  • RAGE, receptor for AGE
  • VKH, Vogt-Koyanagi-Harada
  • Vogt-Koyanagi-Harada disease
  • advanced glycation end products
  • melanocyte

https://doi.org/10.1136/bjo.2005.072678

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes